GLPG0187,一种广谱的INTEGRIN受体拮抗剂,具有抗肿瘤活性 | 1320346-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: GLPG0187,一种广谱的INTEGRIN受体拮抗剂,具有抗肿瘤活性
• 英文名称: L-Alanine, 3-((2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl)-4-pyrimidinyl)amino)-N-((4-methoxyphenyl)sulfonyl)
• 英文别名: (2S)-3-[[2,5-dimethyl-6-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl]pyrimidin-4-yl]amino]-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid
• CAS: 1320346-97-1
• 化学式: C₂₉H₃₇N₇O₅S
• 分子量: 595.7
• InChiKey: CXHCNOMGODVIKB-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  42
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  167
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
  申请人：Phillips Eric

  公开号：US20110237605A1

  公开（公告）日：2011-09-29

  A molecular crystal form of (S)-3-(2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin- 1 -yl)pyrimidin-4-ylamino)-2-(4-methoxyphenylsulfonamido)propanoic acid is characterized by an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 7.44, 14.80, 16.64, and 23.04±0.2°. The molecular crystal can be formulated into pharmaceutical composition for treating or controlling diseases resulting from pathological angiogenesis.

  (S)-3-(2,5-二甲基-6-(4-(5,6,7,8-四氢-1,8-萘啶基-2-基)哌啶-1-基)嘧啶-4-基氨基)-2-(4-甲氧基苯磺酰胺基)丙酸的分子晶体形式，其具有X射线粉末衍射（“XRPD”）谱，包括2θ角度为7.44、14.80、16.64和23.04±0.2°的峰。该分子晶体可以制成药物组合物，用于治疗或控制由病理性血管生成导致的疾病。
• COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR INHIBITING PROGRESSION OF, PATHOGENIC OCULAR NEOVASCULARIZATION
  申请人：Shafiee Afshin

  公开号：US20110189174A1

  公开（公告）日：2011-08-04

  A composition for treating, reducing, ameliorating, alleviating, or inhibiting the progression of, pathological ocular neovascularization comprises an integrin or vitronectin receptor antagonist having any one of Formulae I-XI, as defined herein. The composition can further comprise a VEGF inhibitor. Such composition is administered to an ocular environment by a method such as topical application, periocular injection, intravitreal injection, or intravitreal implantation. The composition can be administered alone or in combination with another procedure chosen to enhance the outcome of the treatment.
• [EN] MOLECULAR CRYSTAL OF (4 -(1,8-NAPHTHYRIDIN-2-YL) PIPERIDIN - 1 -YL ) PYRIMIDINE DERIVATIVE<br/>[FR] CRISTAL MOLÉCULAIRE D'UN DÉRIVÉ DE (4-(1,8-NAPHTYRIDIN-2-YL)PIPÉRIDIN- 1-YL)-PYRIMIDINE
  申请人：BAUSCH & LOMB

  公开号：WO2011119282A1

  公开（公告）日：2011-09-29

  A molecular crystal form of (S)-3-(2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)piperidin- 1 -yl)pyrimidin-4-ylamino)-2-(4- methoxyphenylsulfonamido)propanoic acid is characterized by an X-ray powder diffraction ("XRPD") spectrum that comprises peaks at 2θ angles of 7.44, 14.80, 16.64, and 23.04 ±0.2°. The molecular crystal can be formulated into pharmaceutical composition for treating or controlling diseases resulting from pathological angiogenesis.